Sun Pharmaceutical Industries Europe B.V. - Resultados da pesquisa

Noruega - norueguês - Statens legemiddelverk

oksaliplatin sun 5 mg/ ml

sun pharmaceutical - nederland - oksaliplatin - konsentrat til infusjonsvæske, oppløsning - 5 mg/ ml

Noruega - norueguês - Statens legemiddelverk

fulvestrant sun 250 mg

sun pharmaceutical - nederland - fulvestrant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 250 mg

Noruega - norueguês - Statens legemiddelverk

fyremadel 0.25 mg/0.5 ml

sun pharmaceutical - nederland - ganireliksacetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 0.25 mg/0.5 ml

União Europeia - norueguês - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Noruega - norueguês - Statens legemiddelverk

sunitinib sandoz 12.5 mg

sandoz - københavn - sunitinib - kapsel, hard - 12.5 mg

Noruega - norueguês - Statens legemiddelverk

sunitinib sandoz 25 mg

sandoz - københavn - sunitinib - kapsel, hard - 25 mg

Noruega - norueguês - Statens legemiddelverk

sunitinib sandoz 50 mg

sandoz - københavn - sunitinib - kapsel, hard - 50 mg

Noruega - norueguês - Statens legemiddelverk

sunitinib teva 12.5 mg

teva b.v. - sunitinib - kapsel, hard - 12.5 mg